AstraZeneca files New Drug Application for Brilinta

19th Nov 2009 07:39

Anglo-Swiss drug giant AstraZeneca has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its Brilinta blood cot prevention treatment.The submission for Brilinta, currently known as ticagrelor, follows successful trials and a phase III study that found the drug worked much faster than rival Plavix.It is used to reduce major adverse cardiac events in patients with acute coronary syndrome (ACS), or a drop in blood flow to the heart muscle, such as chest pains and heart attacks.Analysts have high hopes for Brilinta. They think it could be a multi-billion dollar product to compete with Plavix from Bristol-Myers Squibb and Sanofi-Aventis.